Overview

Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

Status:
Active, not recruiting
Trial end date:
2022-05-02
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the pharmacokinetics (PK) of isatuximab. Secondary Objectives: - To evaluate the safety and tolerability of isatuximab. - To assess the preliminary antitumor effect of isatuximab. - To evaluate the immunogenicity of isatuximab.
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi